MX361816B - Suministro intraventricular lento. - Google Patents

Suministro intraventricular lento.

Info

Publication number
MX361816B
MX361816B MX2013013333A MX2013013333A MX361816B MX 361816 B MX361816 B MX 361816B MX 2013013333 A MX2013013333 A MX 2013013333A MX 2013013333 A MX2013013333 A MX 2013013333A MX 361816 B MX361816 B MX 361816B
Authority
MX
Mexico
Prior art keywords
brain
intraventricular delivery
administration
agents
slow
Prior art date
Application number
MX2013013333A
Other languages
English (en)
Inventor
Marco Passini
Seng Cheng
James Dodge
Shihabuddin Lamya
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX361816B publication Critical patent/MX361816B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

Las enfermedades neurológicas, que incluyen enfermedades de almacenamiento lisosomal, pueden ser tratadas exitosamente utilizando la administración intraventricular de agentes terapéuticos para pasar la barrera sanguíneo-cerebral. De manera similar, los agentes de diagnóstico y agentes anestésicos pueden ser administrados al cerebro de esa forma. La administración puede llevarse a cabo lentamente para lograr el máximo efecto. Dicha administración permite mayor penetración de porciones distales del cerebro.
MX2013013333A 2006-02-09 2007-02-08 Suministro intraventricular lento. MX361816B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77145106P 2006-02-09 2006-02-09
PCT/US2007/003382 WO2007095056A2 (en) 2006-02-09 2007-02-08 Slow intraventricular delivery

Publications (1)

Publication Number Publication Date
MX361816B true MX361816B (es) 2018-12-17

Family

ID=38372004

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2013013333A MX361816B (es) 2006-02-09 2007-02-08 Suministro intraventricular lento.
MX2008010125A MX358492B (es) 2006-02-09 2007-02-08 Suministro intraventricular lento.
MX2022005303A MX2022005303A (es) 2006-02-09 2008-08-07 Agentes y usos de los mismos para prevenir y/o tratar enfermedades neurologicas.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2008010125A MX358492B (es) 2006-02-09 2007-02-08 Suministro intraventricular lento.
MX2022005303A MX2022005303A (es) 2006-02-09 2008-08-07 Agentes y usos de los mismos para prevenir y/o tratar enfermedades neurologicas.

Country Status (19)

Country Link
US (3) US20090123451A1 (es)
EP (2) EP3459441A1 (es)
JP (4) JP2009526066A (es)
CN (1) CN101404927A (es)
AR (1) AR059372A1 (es)
BR (1) BRPI0707900A2 (es)
CA (2) CA2641359C (es)
CY (1) CY1121822T1 (es)
DK (1) DK1988823T3 (es)
ES (1) ES2697502T3 (es)
HU (1) HUE040490T2 (es)
IL (2) IL193242A (es)
LT (1) LT1988823T (es)
MX (3) MX361816B (es)
PL (1) PL1988823T3 (es)
PT (1) PT1988823T (es)
RU (1) RU2452368C2 (es)
SI (1) SI1988823T1 (es)
WO (1) WO2007095056A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
ES2697502T3 (es) 2006-02-09 2019-01-24 Genzyme Corp Administración intraventricular lenta
US20120322861A1 (en) 2007-02-23 2012-12-20 Barry John Byrne Compositions and Methods for Treating Diseases
EP2158322B1 (en) * 2007-06-06 2017-05-03 Genzyme Corporation Gene therapy for lysosomal storage diseases
US20110021469A1 (en) * 2007-06-13 2011-01-27 Meythaler Jay M baclofen solution for low-volume therapeutic delivery
BR112012008060A2 (pt) 2009-07-31 2016-11-22 Paxvax Inc vetores baseados em adenovírus
KR20230164773A (ko) * 2009-08-28 2023-12-04 이칸 스쿨 오브 메디슨 엣 마운트 시나이 산성 스핑고미엘리나제 결핍을 치료하기 위한 투여량 단계적 증가 효소 대체 요법
HRP20211520T1 (hr) * 2010-06-25 2021-12-24 Shire Human Genetic Therapies, Inc. Postupci i pripravci za dostavu iduronat-2-sulfataze u središnji živčani sustav
JP2015523998A (ja) 2012-06-19 2015-08-20 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 疾患を治療するための組成物および方法
KR20240093939A (ko) * 2013-05-15 2024-06-24 리젠츠 오브 더 유니버시티 오브 미네소타 중추 신경계로의 아데노-연관 바이러스 매개 유전자 전달
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
EP3684938A1 (en) 2017-09-22 2020-07-29 The Trustees of the University of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8303626D0 (sv) 1983-06-23 1983-06-23 Kabigen Ab A recombinant plasmid a transformant microorganism, a polydoxyrebonucleotide segment, a process for producing a biologically active protein, and the protein thus produced
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5919676A (en) 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
WO1995005864A1 (en) * 1993-08-27 1995-03-02 Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Convection-enhanced drug delivery
JPH10507061A (ja) 1994-04-28 1998-07-14 ザ ユニバーシティ オブ ミシガン アデノウイルス中にパッケージされたプラスミドｄｎａを用いる遺伝子送達ベクターおよびパッケージング細胞株
AU5551996A (en) 1995-04-17 1996-11-07 Board Of Regents, The University Of Texas System An adenovirus helper-virus system
SI0833934T2 (sl) 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6156497A (en) 1996-01-05 2000-12-05 Genetic Therapy, Inc. Recombinase-mediated generation of adenoviral vectors
US5735814A (en) * 1996-04-30 1998-04-07 Medtronic, Inc. Techniques of treating neurodegenerative disorders by brain infusion
RU2179034C2 (ru) 1996-09-13 2002-02-10 Транскариотик Терапиз, Инк. ЛЕЧЕНИЕ В СЛУЧАЕ ДЕФИЦИТА α-ГАЛАКТОЗИДАЗЫ А
US7033598B2 (en) * 1996-11-19 2006-04-25 Intrabrain International N.V. Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal
US6042579A (en) * 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO1999057296A1 (en) 1998-05-01 1999-11-11 Genzyme Corporation Partially deleted adenoviral vectors
US6702945B2 (en) 2000-12-28 2004-03-09 Exxonmobil Research And Engineering Company Ionic membranes for organic sulfur separation from liquid hydrocarbon solutions
US6689756B2 (en) * 2001-03-02 2004-02-10 Integra Lifesciences Corporation Treatment of neurological disease
WO2003049654A1 (en) * 2001-12-07 2003-06-19 Neuron Therapeutics Protection of neurological tissue by direct cns perfusion cooling
CA2547531C (en) * 2002-11-26 2013-11-12 Seacoast Neuroscience, Inc. Buoyant polymer particles for delivery of therapeutic agents to the central nervous system
RU2253486C2 (ru) * 2003-03-03 2005-06-10 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ химиотерапии опухолей центральной нервной системы
CN1781019A (zh) * 2003-03-12 2006-05-31 萨马里坦药品公司 模拟神经系统疾病的动物模型
US20040258666A1 (en) 2003-05-01 2004-12-23 Passini Marco A. Gene therapy for neurometabolic disorders
WO2005002515A2 (en) * 2003-06-20 2005-01-13 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
EP1730183A2 (en) 2004-01-27 2006-12-13 Compugen USA, Inc. Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of endometriosis
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
US20080233655A1 (en) * 2004-03-31 2008-09-25 Children, Youth And Women's Health Service Screening For Lysosomal Storage Disease Status
AR059088A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una proteina para esclerosis lateral amiotrofica
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
ES2697502T3 (es) 2006-02-09 2019-01-24 Genzyme Corp Administración intraventricular lenta
EP2158322B1 (en) 2007-06-06 2017-05-03 Genzyme Corporation Gene therapy for lysosomal storage diseases

Also Published As

Publication number Publication date
EP3459441A1 (en) 2019-03-27
MX358492B (es) 2018-08-22
US11253485B2 (en) 2022-02-22
PT1988823T (pt) 2018-11-22
CN101404927A (zh) 2009-04-08
AR059372A1 (es) 2008-03-26
HUE040490T2 (hu) 2019-03-28
BRPI0707900A2 (pt) 2011-05-10
CY1121822T1 (el) 2020-07-31
WO2007095056A3 (en) 2008-01-10
JP6129685B2 (ja) 2017-05-17
US20090123451A1 (en) 2009-05-14
JP2018024664A (ja) 2018-02-15
EP1988823A2 (en) 2008-11-12
ES2697502T3 (es) 2019-01-24
RU2008136196A (ru) 2010-03-20
IL193242A0 (en) 2009-08-03
EP1988823A4 (en) 2009-02-11
DK1988823T3 (en) 2018-12-03
JP2016028711A (ja) 2016-03-03
JP2014012694A (ja) 2014-01-23
SI1988823T1 (sl) 2018-12-31
IL193242A (en) 2017-11-30
JP6408970B2 (ja) 2018-10-17
JP6617125B2 (ja) 2019-12-11
EP1988823B1 (en) 2018-08-15
PL1988823T3 (pl) 2019-01-31
CA2641359C (en) 2022-10-04
US20190328682A1 (en) 2019-10-31
IL248492A0 (en) 2016-12-29
MX2022005303A (es) 2022-05-16
LT1988823T (lt) 2018-12-10
CA3168881A1 (en) 2007-08-23
US20220370348A1 (en) 2022-11-24
CA2641359A1 (en) 2007-08-23
RU2452368C2 (ru) 2012-06-10
WO2007095056A2 (en) 2007-08-23
JP2009526066A (ja) 2009-07-16

Similar Documents

Publication Publication Date Title
MX358492B (es) Suministro intraventricular lento.
MX349749B (es) Suministro enzimatico intraventricular para enfermedades de almacenamiento lisosomico.
IL273765A (en) Combinations and forms of administration of therapeutic agents and combined treatment
IL171607A (en) Use of botulinum toxin for the treatment of sinusitis-induced headaches
WO2008103993A3 (en) Compositions and methods for treating glycogen storage diseases
WO2005051429A3 (en) Targeted conjugates with a modified saccharide linker
WO2007100675A3 (en) Collagenase for treating cellulite
NZ605865A (en) Cns delivery of therapeutic agents
NZ588648A (en) Suture line administration technique using botulinum toxins
WO2011009020A3 (en) Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
WO2009106991A3 (en) Pyridazine derivatives and their use as therapeutic agents in the treatment of skin disorders
WO2009105432A3 (en) Devices and methods for delivery of a therapeutic agent through a pneumostoma
EP3818991A3 (en) Compositions and methods for treating diseases
NZ606825A (en) Methods and compositions for treating complement-associated disorders
WO2009155439A3 (en) Use of nitrated lipids for treatment of side effects of toxic medical therapies
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2008025790A3 (en) Use of opioid formulations in needle-less drug delivery devices
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2007100590A3 (en) Methods for treating cellulite
WO2006138316A3 (en) Methods for delivering molecules to the central nervous system
WO2009137436A3 (en) Peptide conjugates
WO2009062193A3 (en) Methods for administering corticosteroid formulations
WO2008079818A3 (en) Intravenous administration of water soluble analgesic formulations
WO2007135123A3 (en) Mirtazapine for the treatment of neuropathic pain
WO2007105218A3 (en) Composition and method for brain tumor therapy